Sixteen AML patients were tested who showed an immune response against at least one of these antigens (PRAME, WT-1 or NPM-1; Pt 1-4 PRAME, Pt 5-8 WT-1 and Pt 9-16 NPM1). This evidence concerns the gene NPM1 and acute myeloid leukemia.